SEP 01, 2016
In this interview from ASRS 2016, Dr. Charles C. Wykoff discusses his subgroup analysis from the RISE and RIDE studies which shows that patients with high-risk non-proliferative diabetic retinopathy can greatly benefit from ranibizumab treatment. Dr. Wykoff’s study found that 75% of eyes with baseline retinopathy severity levels of 47-53 showed at least 2 steps of retinopathy improvement at 1 year, which was maintained through years 2 and 3 of follow-up. This work, alongside other recent research, suggests that DR may have a significant impact on patients’ visual quality of life even before progression to DME. Dr. Wykoff also advocates switching to PRN or quarterly injections instead of an abrupt cessation of anti-VEGF therapy to stabilize retinal vasculature and prevent recurrence.